GlycoMimetics Inc. (GLYC) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Comparing side by side

GlycoMimetics Inc. (NASDAQ:GLYC) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GlycoMimetics Inc. 6 0.00 22.45M -1.32 0.00
Regeneron Pharmaceuticals Inc. 373 1.96 81.35M 18.21 20.45

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 provides GlycoMimetics Inc. and Regeneron Pharmaceuticals Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
GlycoMimetics Inc. 403,929,541.73% -30.7% -28.8%
Regeneron Pharmaceuticals Inc. 21,791,540.54% 22.3% 16.6%

Volatility & Risk

GlycoMimetics Inc.’s volatility measures that it’s 161.00% more volatile than Standard and Poor’s 500 due to its 2.61 beta. Regeneron Pharmaceuticals Inc. has a 1.19 beta and it is 19.00% more volatile than Standard and Poor’s 500.


GlycoMimetics Inc.’s Current Ratio is 16.7 while its Quick Ratio is 16.7. On the competitive side is, Regeneron Pharmaceuticals Inc. which has a 4 Current Ratio and a 3.5 Quick Ratio. GlycoMimetics Inc. is better positioned to pay off short and long-term obligations compared to Regeneron Pharmaceuticals Inc.

Analyst Recommendations

In next table is given GlycoMimetics Inc. and Regeneron Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
GlycoMimetics Inc. 0 2 1 2.33
Regeneron Pharmaceuticals Inc. 0 5 1 2.17

GlycoMimetics Inc. has an average price target of $7.67, and a 57.49% upside potential. On the other hand, Regeneron Pharmaceuticals Inc.’s potential downside is -8.24% and its consensus price target is $358.57. The data from earlier shows that analysts opinion suggest that GlycoMimetics Inc. seems more appealing than Regeneron Pharmaceuticals Inc.

Insider and Institutional Ownership

The shares of both GlycoMimetics Inc. and Regeneron Pharmaceuticals Inc. are owned by institutional investors at 98.1% and 73.8% respectively. Insiders held 0.8% of GlycoMimetics Inc. shares. Competitively, 19.4% are Regeneron Pharmaceuticals Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
GlycoMimetics Inc. 1.87% 6.58% 62.77% -43.49% -44.89% -36.75%
Regeneron Pharmaceuticals Inc. 0.88% 14.72% 33.43% 22.35% -2.47% -0.33%

For the past year GlycoMimetics Inc. was more bearish than Regeneron Pharmaceuticals Inc.


Regeneron Pharmaceuticals Inc. beats on 8 of the 13 factors GlycoMimetics Inc.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.